Lumenis showcased its new OptiLight technology for the treatment of dry eye disease (DED) to the Australian and New Zealand market at a recent virtual event, sharing insights into its application for clinics and their patients.
US-based Aldeyra Therapeutics announced it’s 0.25% reproxalap ophthalmic solution met its primary endpoint in a phase 2 clinical trial in dry eye disease (DED) patients. Of the 158 patients enrolled
A modified technique for minor salivary gland transplantation (MSGT) as a treatment for severe dry eye disease (DED) led to long-term improvements in visual acuity, ocular surface environment and
Ocular Therapeutix said a phase-2 study of its OTX-CSI insert for the treatment of dry-eye disease (DED) missed its primary endpoint of increased tear production. The US-based clinical trial was
Ciclosporin (Ikervis) has been listed on the Pharmaceutical Benefits Scheme (PBS) in Australia, saving around 7,500 severe keratitis patients with dry eye disease (DED) an estimated A$900 each per year, said Greg Hunt, Minister for Health and Aged Care.
With a large (and growing) number of New Zealanders undergoing cancer therapy, eyecare professionals should be cognisant of the ocular complications that can result from many of these treatments to ensure their timely and appropriate diagnosis and management. Although chemotherapy remains a mainstay
Oyster Point Pharma has received US FDA approval for Tyrvaya (varenicline) nasal spray for dry eye disease (DED). "The approval of Tyrvaya nasal spray marks a milestone for patients and eyecare
Lumenis has received the US Food and Drug Administration’s (FDA) De Novo authorisation for its newest intense pulsed light (IPL) device OptiLight, designed to improve signs of dry eye
In theory, fitting scleral lenses for my dry eye patients was a logical evolution for both my dry eye and rigid gas permeable (RGP) contact lens practice specialities, but there were a few obstacles to making it a success in practice. Time was a significant issue. Dry eye patients typically have num
Diagnostic and subclassification testing of dry eye disease (DED) is particularly important for informing tailored and optimised management plans for patients in clinical practice, as well as for guiding participant recruitment and the evaluation of outcome measures in population-based epidemiology
In recent years there has been growing interest in the potential link between a number of modifiable lifestyle risk factors and the development of dry eye disease, the goal being to inform cost-effective disease prevention strategies at the population level. This is important, since the public healt
As an optometrist who specialises in dry eye disease (DED), I am constantly trying to stay on top of the latest research and developments, so it was with great enthusiasm that I embarked on the British Contact Lens Association (BCLA)’s dry eye management and contact lens retention certificate course
